Biotech · Private company
Aptose Biosciences Inc.
Track this companyFree. Adds Aptose Biosciences Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Azacitidine for Intravenous InfusionPhase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- TuspetinibPhase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- Venetoclax Oral TabletPhase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- APTO-253Phase 1 · Acute Myelogenous Leukemia in RelapseClinicalTrials.gov · fetched Nov 12, 2026
- CG-806Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CG-806Phase 1 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSPHASE1 · TERMINATED · started Oct 6, 2020ClinicalTrials.gov NCT04477291 · fetched Nov 12, 2026
- A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasPHASE1 · TERMINATED · started Apr 30, 2019ClinicalTrials.gov NCT03893682 · fetched Nov 12, 2026
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaPHASE1_PHASE2 · RECRUITING · started Mar 11, 2019ClinicalTrials.gov NCT03850574 · fetched Nov 12, 2026
- A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSPHASE1 · TERMINATED · started Oct 1, 2014ClinicalTrials.gov NCT02267863 · fetched Nov 12, 2026